Combination drug study for advanced colorectal cancer with liver spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called BioTTT001 combined with toripalimab and regorafenib for people with colorectal cancer that has spread to the liver. It is for those who have tried at least two prior treatments or cannot have standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have colorectal cancer that has spread to the liver and you have already tried at least two standard treatments or cannot take them.
- You have at least one tumor that can be measured on scans.
- Your blood counts and liver/kidney function are within acceptable ranges.
- You are willing to use contraception during the study.
- You have not had certain prior treatments (like other adenovirus drugs or certain chemotherapies) within specific time frames.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
This study tests a combination of three drugs for patients with colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug combination (ABT-301, tislelizumab, and bevacizumab) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
This trial tests a new drug called BioTTT001 combined with chemotherapy (SOX) and another drug (toripalimab) for stomach cancer that has spread to the lining of the abdomen. It is for people who have not had treatment for advanced disease or whose cancer came back more than 6 months after earlier treatment.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.